ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
47 announcements with these filters
Sat Kartar Life signed an LOI for a 20-bed hospital-cum-therapy centre in Dehradun at ₹0.70 Crore. The facility is expected to be operational by December 2026.
Sat Kartar Life Limited has re-appointed M/s. Nidhi Bansal & Co. as its statutory auditor for a further term of five consecutive years.
Sat Kartar Life Limited held its 14th Annual General Meeting on August 28, 2026. Shareholders considered financial statements, director re-appointments, auditor appointments, and a final dividend of Rs.0.70.
Sat Kartar Life Limited plans to establish a new hospital-cum-therapy centre in Gurugram with a ₹1 crore investment. The facility will feature 10-15 beds.
Sat Kartar Life Limited announced the dispatch of letters to unregistered shareholders, providing a web link to access the Annual Report 2025-2026 for the upcoming AGM.
Sat Kartar Life Limited has issued a notice for its 14th Annual General Meeting, scheduled for August 28, 2026, to transact ordinary and special business.
Sat Kartar Life Limited re-appointed M/s. Nidhi Bansal & Co as Statutory Auditors for a five-year term. The board approved this decision during its meeting on July 31, 2026.
Sat Kartar Life Limited recommended a final dividend of ₹0.70 per equity share for FY2026. The board fixed August 21, 2026, as the record date for payment.
Sat Kartar Life Limited has entered into a common empanelment agreement with the General Insurance Council to facilitate cashless medical treatment.
Sat Kartar Life Ltd received NSE trading approval for 50,400 preferentially allotted shares. The shares are locked in till January 29, 2027.
Sat Kartar Life Limited commenced commercial operations in the USA via its subsidiary. The company established an office in Texas to expand its global wellness presence.
Sat Kartar Life expanded its global footprint by commencing operations in the USA. The expansion involves establishing a subsidiary and office in Texas.
Sat Kartar Life Limited received NABH accreditation for its hospital, valid until May 2029. This enhances patient confidence and supports future empanelments.
Sat Kartar Life Limited received NABH Accreditation for its Sanjeevan Hospital in New Delhi. This certification validates service quality and supports future healthcare empanelment opportunities.
Sat Kartar Life allotted 26,95,200 convertible warrants at ₹172 each via preferential issue, raising ₹46.36 Crore. The company received 25% upfront subscription money from fourteen investors.
Sat Kartar Life Limited allotted 50,400 equity shares via preferential issue to Viney Growth Fund. The company raised ₹0.87 Crore to strengthen its overall capital base.
Sat Kartar Life Limited appointed M/s. R. S. Goel & Co and M/s. Rawal & Co. as Internal and Secretarial Auditors. The appointments cover financial year 2026-27.
Sat Kartar Life allotted 50,400 equity shares to Viney Growth Fund via a preferential issue. The company raised ₹0.87 Crore to strengthen its financial position.
Sat Kartar Life Limited allotted 26.95 lakh convertible warrants via preferential issue. The company raised ₹1.16 Crore as upfront subscription money to strengthen its capital base.
Sat Kartar Life approved allotting equity shares and convertible warrants totaling ₹47.22 Crore. The company also appointed new secretarial and internal auditors for FY 2026-27.
Sat Kartar Life Limited expanded its business activities into advertising, branding, and media planning. This strategic move aims to diversify revenue and leverage digital marketing expertise.
Sat Kartar Life Limited filed its annual Structured Digital Database compliance certificate for FY2026. The auditor confirmed total compliance with insider trading regulations.
Sat Kartar Life Limited clarified missing IPO proceeds utilization details for its March 2026 results. The company raised ₹33.80 Crore, correcting a prior regulatory reporting omission.
Sat Kartar Life Limited conducted an EGM on May 13, 2026. Shareholders approved the preferential issuance of equity shares and warrants to non-promoter entities.
Sat Kartar Life reported 23% revenue growth crossing ₹200cr in FY26. Transitioning from product-focused to an integrated Ayurvedic healthcare ecosystem including hospitals.
Sat Kartar Life Limited received NSE in-principle approval for issuing 2,824,800 equity shares. The allotment follows warrant conversions from a prior preferential issue.
Sat Kartar Life Limited is adopting a new spiritual and wellness business line. The expansion leverages its existing digital reach to drive revenue and operational synergies.
Sat Kartar Life transitioned from a product-focused entity to a healthcare ecosystem, delivering record growth in FY26. Management is aggressively targeting 150% revenue growth by FY28 through massive hospital bed expansion and US market entry.
Sat Kartar Life Limited received a no-objection letter from the NSE to reclassify SK Sarthi Private Limited from 'Promoter Group' to 'Public' shareholder category. The entity holds less than 1% of the company's paid-up capital, making shareholder approval unnecessary. This regulatory milestone follows the company's initial application submitted in January 2026.
Sat Kartar Life Limited reported strong FY26 results with consolidated revenue of ₹200.70 Crore, up 23.19% YoY. Net profit (PAT) rose 74.31% to ₹17.10 Crore. The company launched its first 30-bed Ayurveda hospital in Delhi and raised ₹48.58 Crore to support its expansion towards a ₹500 Crore revenue target by FY28.